Latent Labs has officially launched its web-based AI model, LatentX, aimed at democratizing protein design. This release comes approximately six months after the company emerged from stealth mode, securing $50 million in funding. The model is designed to allow academic institutions, biotech startups, and pharmaceutical companies to create novel proteins directly through a web browser using natural language inputs.
According to Simon Kohl, CEO and founder of Latent Labs, the model has “achieved state-of-the-art on different metrics” when tested against proteins developed in a physical laboratory. Kohl, who previously co-led the protein design team for DeepMind’s AlphaFold, emphasized that a significant percentage of proteins generated by LatentX are expected to be viable in laboratory tests.
LatentX represents a significant advancement in the field of protein design, going beyond naturally occurring proteins to generate entirely new molecular structures, such as nanobodies and antibodies, with precise atomic configurations. This innovative approach aims to expedite the development of new therapeutics significantly.
Distinctive Features of LatentX
Kohl explained that while AlphaFold excels in predicting existing protein structures, it does not facilitate the generation of new proteins. “AlphaFold is a model for protein structure prediction. It allows you to visualize existing structures, but it doesn’t let you generate new proteins,” he noted. This distinction positions LatentX as a powerful tool in the realm of protein engineering.
Unlike other AI-driven drug discovery companies, such as Xaira and Recursion, which focus on developing proprietary medicines, Latent Labs plans to license its model for external use. Kohl pointed out that not every organization has the resources to develop its own AI infrastructure. “Not every company is in a position to build their own AI models, to have their own AI infrastructure, and to have their own AI teams,” he stated.
While LatentX is currently available for free, Latent Labs intends to introduce paid advanced features and functionalities in the future. This approach aligns with the strategies of other companies in the field, including Chai Discovery and EvolutionaryScale, which also provide open-sourced AI foundational models for drug discovery.
Strong Backing and Future Prospects
Latent Labs has garnered support from notable investors, including Radical Ventures, Sofinnova Partners, and prominent figures such as Google’s Chief Scientist Jeff Dean, Dario Amodei of Anthropic, and Mati Staniszewski, CEO of Eleven Labs. This strong backing underscores the potential impact of LatentX on the scientific community and the broader field of biotechnology.
As the need for innovative therapeutics continues to grow, Latent Labs’ advancements in protein design through AI may not only accelerate research but also lead to breakthroughs in understanding and treating various diseases. The launch of LatentX marks an important milestone in making cutting-edge biotechnological tools accessible to a wider range of researchers and organizations.
